Novartis' chronic lung disease drug wins approval in EU, Japan

09/25/2013 | PharmaTimes (U.K.)

Novartis obtained approval from the European Commission to market its once-daily Ultibro Breezhaler, or QVA149, as a maintenance therapy for chronic obstructive pulmonary disease. The Japanese Ministry of Health, Labour and Welfare approved Ultibro Inhalation Capsules, delivered using the Breezhaler device, to treat symptoms of COPD.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC